Introduction
============

The quality of life of oncologic patients is significantly influenced by their psychiatric co-morbidities. Major depressive episodes (MDE), with a reported prevalence of 14.3% in cancer patients \[[@b1-cm-86-274]\], increase the subjective distress, impact on the patient's adherence to specific therapies \[[@b2-cm-86-274]\] and are considered to prolong the time spent in medical care units \[[@b3-cm-86-274]\], and reduce survival rates of malignancy suffering patients \[[@b4-cm-86-274],[@b5-cm-86-274],[@b6-cm-86-274]\]. They also impact on the quality of life, aggravating the fatigue, the insomnia and the appetite loss, and also influence emotional, social and physical functioning \[[@b7-cm-86-274]\].

Considering these issues, the correct approach of this psychiatric disorder should become one of the main goals of a complex interdisciplinary evaluation of breast cancer patients.

Aims
====

The main objective of the study was to compare the quality of life aspects of metastatic breast cancer patients undergoing chemotherapy, from the perspective of the presence or the absence of an associated MDE.

Patients and methods
====================

A number of 100 successive metastatic breast cancer patients undergoing chemotherapy in the Day Care Unit of the Oncology Institute "Ioan Chiricuţă" Cluj-Napoca were evaluated, all having stage IV breast cancer and informed of the prognosis of the disease. Exclusion criteria were age under 18, brain metastasis, psychotropic medication use in the last 6 months, substance abuse or addiction, potentially neurotoxic drugs, others than cancer therapies, unable or unwilling to sign the informed consent. One patient was subsequently excluded as she proved to have had brain metastasis. General recorded data are mentioned in [table I](#tI-cm-86-274){ref-type="table"}.

The psychiatric diagnosis was established according to the criteria of the American Psychiatric Association in the Diagnosis and Statistical Manual of Mental Disorders - fourth edition text revised (DSM-IV TR) \[[@b8-cm-86-274]\] in correlation with the Romanian version of Mini International Neuropsychiatric Interview 6 (M.I.N.I. 6), with the additional section for adjustment disorders, extracted from M.I.N.I. 6 Plus, translated and validated with author's permission. For the evaluation of the quality of life the patients were asked to answer the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), version 3.0 and the supplementary breast module (QLQ-BR23) \[[@b9-cm-86-274]\].

Data were analyzed using the Statistical Pack for Social Sciences (SPSS), version 13.0, including the t-Student test for equality of means, and the non-parametric Mann-Whitney test for independent groups. We compared the scores of the quality of life scales in the group of major depressive episode with those without M.I.N.I. 6 diagnosis. The variable distribution was tested with Skewness and Kurtosis and the differences between groups were evaluated using the chi-square test. The adjusted means were compared using the general linear model. The study was approved by the Ethics Committee of the University of Medicine and Pharmacy "Iuliu Haţieganu" Cluj-Napoca.

Results
=======

The age mean in the group was 56.07 years, with a Standard Deviation (SD) of 9.988. General data results are presented in [table II](#tII-cm-86-274){ref-type="table"}.

The most frequent metastasis location was bones. The majority of subjects had undergone mastectomy (74.7%) and both chemo and radiotherapy (85%), and 73.7% were administered dexamethasone the day prior to evaluation (8 to 24 mgs/day). Opioids were part of the therapeutic plan in 29.3% of subjects and 34 patients suffered from co-morbid hypertension, diabetes, asthma, ischemic heart disease, obesity and dyslipidemia.

According to the structured interview and to the DSM-IV TR, the psychiatric disorders identified in the study group were those mentioned in the [figure 1](#f1-cm-86-274){ref-type="fig"}.

We found statistically significant differences between the two groups concerning the living environment, the marital status, the social support, the metastasis site, the surgery type, the specific therapies, the dexamethasone and opioids use and the somatic co-morbidities ([table III](#tIII-cm-86-274){ref-type="table"}).

Considering trial reports mentioning that these factors influence the quality of life indicators \[[@b10-cm-86-274],[@b11-cm-86-274],[@b12-cm-86-274],[@b13-cm-86-274],[@b14-cm-86-274]\], the adjusted means for the above parameters of the EORTC QLQ-C30 and QLQ-BR 23 scales were calculated and compared between the two subgroups. The adjusted mean scores of the functional scales were significantly lower for the depressed subjects group for physical, role, emotional and social functioning ([table IV](#tIV-cm-86-274){ref-type="table"}).

For the symptom scales within the QLQ C-30 questionnaire, statistically significant differences were documented, as presented in [table V](#tV-cm-86-274){ref-type="table"}.

As expected, the adjusted mean scores for quality of life/general health status were significantly lower in the group with depressive patients, with a Mann-Whitney test p value of 0.006.

The functional and symptom scales from the QLQ-BR 23 module were also compared between the two subgroups, with significant differences for the items mentioned in [table VI](#tVI-cm-86-274){ref-type="table"}.

Discussion
==========

As compared with the results of other studies, which report a prevalence of major depression episodes in breast cancer patients varying between 4.7% \[[@b15-cm-86-274]\] and 11% \[[@b16-cm-86-274]\], the rate of MDE in our study was much higher, most probably due to the characteristics of the enrolled subjects, the poor socio-economic comfort, but also possibly because, in contrast with other studies \[[@b17-cm-86-274]\], we used a complex diagnostic approach, thus enhancing the fidelity of the diagnostic process.

The emotional dimension of the EORTC QLQ C-30 correlated with the psychiatric diagnosis. The deficient physical functioning of the depressive cancer patients was mentioned by other authors \[[@b18-cm-86-274]\], and the association between pain and depression was noted in multiple cancer population studies \[[@b19-cm-86-274],[@b20-cm-86-274],[@b21-cm-86-274]\] and our research confirms it. Fatigue, appetite loss, constipation and insomnia are specific symptoms of the major depressive episodes, but also generated by chemotherapy. Fatigue is the most frequently encountered symptom in cancer \[[@b22-cm-86-274]\], and our results suggest that the emotional distress impacts on this aspect of the quality of life.

The cancer related insomnia is correlated in some studies with the depressive symptoms \[[@b23-cm-86-274]\], and was considered to be the main symptom that differentiates depressive from non-depressive cancer patients \[[@b24-cm-86-274]\]. The significantly higher scores for appetite loss, insomnia, nausea and vomiting and dyspnea in the depressive patients group in our study suggest that the major depressive episodes mainly affect the quality of life of these patients. Chemotherapy has a negative impact on the sexual life \[[@b25-cm-86-274]\]. In our study both sexual functioning and satisfaction were deficient in the subgroup of depressed patients, confirming the results obtained in other studies \[[@b26-cm-86-274]\]. The future perspective scale had lower mean scores in the depressed patients group, and the quality of life/general health status, reflecting most accurately the subjective perception of individual's existential satisfaction, was deficient in patients with co-morbid major depressive episodes, thus confirming that mood disorders impact on metastatic breast cancer patients' quality of life.

Conclusions
===========

1.  Patients with metastatic breast cancer undergoing chemotherapy and diagnosed with major depressive episode had significantly lower scores in our study for physical, role, emotional, social, sexual functioning, sexual enjoyment and future perspective comparing to those without M.I.N.I. 6 diagnosis.

2.  The adjusted scores for fatigue, nausea and vomiting, pain, dyspnea, appetite loss and constipation were significantly higher in the depressive patients group comparing to those without MINI 6 diagnosis.

3.  The adjusted mean scores for quality of life/general health status, were not normally distributed and significantly lower in the group of depressive patients.
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###### 

General data.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Socio-demographic Age (years)Living environmentMarital statusPreexisting financial difficultiesSocial support
  Cancer history Time since diagnosis (months)Time since recurrence (months)Metastasis site
  Cancer therapy history Type of surgery (mastectomy/breast conserving)Type of therapy (chemotherapy/radiotherapy/combined)Dexamethasone premedication (yes/no)Opioids administration (yes/no)
  Other Somatic co-morbidities
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Living environment, marital status and social support.

                       Number   Percent
  -------------------- -------- ---------
  Living environment            
   Urban               79       79.8
   Rural               20       20.2
                                
  Marital status                
   Unmarried           9        9.1
   Married             68       68.7
   Divorced            8        8.1
   Widow               14       14.1
                                
  Social support                
   No                  20       20.2
   Yes                 79       79.8
                                
  Total                99       100.0

###### 

Significantly different parameters.

  -------------------------------------------------------------------------------------------------------------------------------------------
                                                                                              M.I.N.I. diagnosis   Total         
  ------------------- ----------------------------------- ----------------------------------- -------------------- ------------- ------------
  Environment\        urban                               Count % within diagnostic M.I.N.I   49 (86.0%)           22 (75.9%)    71 (82.6%)
  **p\<0.0001**                                                                                                                  

  rural               Count % within diagnostic M.I.N.I   8 (14.0%)                           7 (24.1%)            15 (17.4%)    

                                                                                                                                 

  Marital status\     unmarried                           Count % within diagnostic M.I.N.I   5 (8.8%)             4 (13.8%)     9 (10.5%)
  **p\<0.0001**                                                                                                                  

  married             Count % within diagnostic M.I.N.I   39 (68.4%)                          19 (65.5%)           58 (67.4%)    

  divorced            Count % within diagnostic M.I.N.I   3 (5.3%)                            4 (13.8%)            7 (8.1%)      

  widow               Count % within diagnostic M.I.N.I   10 (17.5%)                          2 (6.9%)             12 (14.0 %)   

                                                                                                                                 

  Social support\     no                                  Count % within diagnostic M.I.N.I   9 (15.8%)            8 (27.6%)     17 (19.8%)
  **p\<0.0001**                                                                                                                  

  yes                 Count % within diagnostic M.I.N.I   48 (84.2%)                          21 (72.4%)           69 (80.2%)    

                                                                                                                                 

  Metastasis site\    lung                                Count % within diagnostic M.I.N.I   6 (10.5%)            2 (6.9%)      8 (9.3%)
  **p\<0.0001**                                                                                                                  

  bone                Count % within diagnostic M.I.N.I   26 (45.6%)                          19 (65.5%)           45 (52.3%)    

  liver               Count % within diagnostic M.I.N.I   6 (10.5%)                           2 (6.9%)             8 (9.3%)      

  multiple            Count % within diagnostic M.I.N.I   19 (33.3%)                          6 (20.7%)            25 (29.1%)    

                                                                                                                                 

  Surgery\            without                             Count % within diagnostic M.I.N.I   7 (12.3%)            5 (17.2%)     12 (14.0%)
  **p\<0.0001**                                                                                                                  

  breast conserving   Count % within diagnostic M.I.N.I   8 (14.0%)                           2 (6.9%)             10 (11.6%)    

  mastectomy          Count % within diagnostic M.I.N.I   42 (73.7%)                          22 (75.9%)           64 (74.4%)    

                                                                                                                                 

  Specific therapy\   chemotherapy                        Count % within diagnostic M.I.N.I   6 (10.5%)            7 (24.1%)     13 (9.3%)
  **p\<0.0001**                                                                                                                  

  combined            Count % within diagnostic M.I.N.I   51 (89.5%)                          22 (75.9%)           73 (84.9%)    

                                                                                                                                 

  Dexamethasone\      yes                                 Count % within diagnostic M.I.N.I   17 (29.8%)           6 (20.7%)     23 (26.7%)
  **p\<0.0001**                                                                                                                  

  no                  Count % within diagnostic M.I.N.I   40 (70.2%)                          23 (79.3%)           63 (73.3%)    

                                                                                                                                 

  Opioids\            no                                  Count % within diagnostic M.I.N.I   46 (80.7%)           17 (58.6%)    63 (73.3%)
  **p\<0.0001**                                                                                                                  

  yes                 Count % within diagnostic M.I.N.I   11 (19.3%)                          12 (41.4%)           23 (26.7%)    

                                                                                                                                 

  Co-morbidities\     no                                  Count % within diagnostic M.I.N.I   39 (68.4%)           40 (69.0%)    79 (68.7%)
  **p\<0.0001**                                                                                                                  

  yes                 Count % within diagnostic M.I.N.I   18 (31.6%)                          18 (31.0%)           36 (31.3%)    
  -------------------------------------------------------------------------------------------------------------------------------------------

###### 

Functional QLQ C-30 scales.

  Adjusted values[\*](#tfn2-cm-86-274){ref-type="table-fn"}   M.I.N.I. 6 diagnostic   N         Mean       SD         p
  ----------------------------------------------------------- ----------------------- --------- ---------- ---------- -----------
  Physical functioning                                        Without                 57        69.5706    16.30332   **0.032**
  MDE                                                         29                      62.0988   11.92021              
                                                                                                                      
  Role functioning                                            Without                 57        56.5939    22.38332   **0.002**
  MDE                                                         29                      39.3289   24.7091               
                                                                                                                      
  Emotional functioning                                       Without                 57        79.0822    12.25850   **0.000**
  MDE                                                         29                      59.8023   17.30494              
                                                                                                                      
  Social functioning                                          Without                 57        61.5194    18.26168   **0.000**
  MDE                                                         29                      45.1633   16.59108              

Adjustment made for living environment, marital status, social support, metastasis site, surgery type, specific therapies, dexamethasone and opioids use, somatic comorbidities.

p significant when \<0.05

###### 

Symptom QLQ C-30 scales.

  Adjusted values[\*](#tfn3-cm-86-274){ref-type="table-fn"}   M.I.N.I. 6 diagnostic   N         Mean       SD         p
  ----------------------------------------------------------- ----------------------- --------- ---------- ---------- -----------
  Fatigue                                                     Without                 57        37.4560    16.92506   **0.000**
  MDE                                                         29                      54.7204   16.78855              
                                                                                                                      
  Nausea and vomiting                                         Without                 57        13.5221    13.61682   **0.001**
  MDE                                                         29                      25.1403   18.73474              
                                                                                                                      
  Pain                                                        Without                 57        37.2928    20.09162   **0.001**
  MDE                                                         29                      51.9666   18.15807              
                                                                                                                      
  Dyspnea                                                     Without                 57        20.3837    23.68669   **0.049**
  MDE                                                         29                      31.1945   23.65868              
                                                                                                                      
  Insomnia                                                    Without                 57        34.0131    28.48857   **0.002**
  MDE                                                         29                      56.1293   31.90997              
                                                                                                                      
  Appetite loss                                               Without                 57        22.8285    21.83413   **0.016**
  MDE                                                         29                      39.8209   32.95147              

Adjustment made for living environment, marital status, social support, metastasis site, surgery type, specific therapies, dexamethasone and opioids use, somatic co-morbidities.

###### 

The QLQ-BR23 scales.

  Adjusted values[\*](#tfn4-cm-86-274){ref-type="table-fn"}   M.I.N.I. 6 diagnosis   N         Mean       SD         p
  ----------------------------------------------------------- ---------------------- --------- ---------- ---------- -----------
  Sexual functioning                                          Without                57        11.2369    9.17665    **0.000**
  MDE                                                         29                     3.6497    6.97574               
                                                                                                                     
  Sexual enjoyment                                            Without                57        48.1444    25.09479   **0.026**
  MDE                                                         29                     11.1100   19.24308              
                                                                                                                     
  Future perspective                                          Without                57        52.3374    20.67072   **0.005**
  MDE                                                         29                     38.9928   19.17981              

Adjustment made for living environment, marital status, social support, metastasis site, surgery type, specific therapies, dexamethasone and opioids use, somatic co-morbidities.
